Psychedelic Therapy Training in Canada: Pathways, Certification, and Programs (2026 Guide)

Psychedelic-assisted therapy (PAT) training prepares licensed Canadian mental-health clinicians to deliver supervised therapy with regulated psychedelic medicines. This guide covers what the training builds, the federal and provincial regulatory landscape, ATMA CENA's three pathways (Essentials, Clinical, Prescriber), substance-specific competencies, certification and continuing-education (CE) credits, eligibility by profession, the course structure, online versus in-person delivery, and a step-by-step path from licence to practice.

Key takeaways

• Psychedelic-assisted therapy in Canada operates under two regulatory tracks: Health Canada's Special Access Program (for psilocybin and MDMA) and provincial off-label rules (for ketamine).
• Health Canada SAP approval rates for psilocybin and MDMA dropped sharply through 2025 and remain case-by-case [PsyCan 2025]. Training prepares clinicians whether or not specific patients receive SAP authorization.
• ATMA CENA offers three sequential pathways: Essentials, Clinical, and Prescriber. Each is anchored by the Psychedelic-Assisted Therapy Foundations course (14 hours) and adds advanced courses, supervised practicum, and substance-specific modules.
• Training is open to physicians, psychologists, registered psychotherapists, registered counsellors, registered nurses, and registered social workers, with eligibility varying by province.
• Continuing-education recognition varies by regulator. ATMA CENA's specific accreditation status by regulator is listed on the certification page.

What is psychedelic-assisted therapy training?

PAT training prepares a licensed mental-health clinician to deliver three components beyond conventional psychotherapy: substance-specific pharmacology and physiology, supervised dosing-day skills, and integration psychotherapy. The medicine itself is not the treatment. The therapeutic relationship, the preparation, and the integration are the active ingredients of clinical effect [Hartogsohn 2018]. Training therefore layers PAT-specific competencies on top of a clinician's existing licensure rather than replacing core psychotherapy skills.

The first published competency framework for psychedelic therapist training defined six core competencies (empathetic abiding presence, trust enhancement, spiritual intelligence, knowledge of physical and psychological effects, self-awareness and ethical integrity, and proficiency in complementary techniques) and twelve curricular areas required for adequate preparation [Phelps 2017]. A four-component psilocybin therapist training program subsequently evaluated 65 clinicians across the United States, Canada, and Europe and reported that all 37 surveyed trainees rated the training "very good" or "excellent" overall, with clinical training and direct participant care described as the most beneficial elements [Tai et al. 2021].

Programs that focus on theory alone, without supervised practicum and a regulatory layer, leave clinicians unprepared to enter clinical practice. Health Canada's risk-management expectations for clinical trials state that "during the phase in which the drug is being administered to the participants, there should be a minimum of two therapists present" and that "any unlicensed members of the therapy team should be under the direct supervision of a licensed therapist" [Health Canada 2022]. ATMA CENA's pathways are designed to build all three competency layers in sequence.

Canada's regulatory landscape for psychedelic therapy

A clinician evaluating PAT training in Canada needs working knowledge of two regulatory layers: federal access pathways for the medicines themselves and provincial scope-of-practice rules for each profession.

Federal: Health Canada and the Special Access Program

Psilocybin and MDMA remain Schedule III restricted drugs under the Controlled Drugs and Substances Act. They are not commercially approved medicines. Patient access for clinical use is available only through Health Canada's Special Access Program (SAP). In January 2022, Health Canada amended SAP regulations to formally include psilocybin and MDMA, and issued a class exemption that streamlines aspects of the application process for psychedelic-assisted psychotherapy [Health Canada 2022]. The conditions Health Canada has named within scope of SAP for psychedelic-assisted psychotherapy are end-of-life distress and treatment-resistant major depressive disorder for psilocybin, and post-traumatic stress disorder for MDMA.

SAP authorization is not guaranteed. The Psychedelic Association of Canada published an analysis in September 2025 documenting an approximately 50 percent year-over-year decline in SAP approvals for psilocybin and MDMA, with prescribers receiving fifteen-page rejection letters and patients pursuing mandamus applications in court [PsyCan 2025]. As of May 2026, this access bottleneck is the most consequential regulatory fact a Canadian clinician should understand before training. Training programs remain valuable independent of SAP approval rates because preparation and integration competencies apply to clinical-trial contexts, ketamine-assisted therapy, and patients whose physicians are pursuing SAP authorization.

A separate Health Canada notice describes the regulator's expectations for clinical trials involving psychedelic-assisted psychotherapy, including the requirement that "therapists would be properly trained on evidence-informed protocols for psychedelic-assisted psychotherapy, and be licensed to provide psychotherapy by a regulatory body (if applicable in their jurisdiction)" [Health Canada 2022]. Health Canada permits only synthetic psilocybin in the SAP context at this time. Natural psilocybin is not permitted.

Provincial: regulators of medical and psychotherapy practice

Each province's regulator governs the practice of medicine, psychology, psychotherapy, counselling, nursing, and social work. The relevant regulators for PAT practice include:

• Alberta: College of Physicians and Surgeons of Alberta (CPSA) for ketamine and physician-led PAT; College of Alberta Psychologists (CAP) for psychology practice. CAP issued the first provincial-college Practice Guideline on Psychedelic-Assisted Psychotherapy in Canada on June 30, 2025, establishing scope, knowledge, safety, and competence requirements for Alberta psychologists [CAP 2025]. CPSA additionally requires that PAT "must be provided within a CPSA-accredited medical facility by a psychiatrist or a physician in consultation with a psychiatrist" [CPSA 2026].
• Ontario: College of Physicians and Surgeons of Ontario (CPSO); College of Registered Psychotherapists of Ontario (CRPO). CRPO's comprehensive Practice Standards came into effect January 1, 2024. As of May 2026, CRPO is "in the process of developing guidance on the legal frameworks for psychedelic-assisted therapy" and has not yet finalized comprehensive PAP-specific standards [CRPO]. Interim principles based on existing standards apply, and CPSO has not issued a ketamine-specific or PAT-specific policy.
• British Columbia: College of Physicians and Surgeons of BC (CPSBC). CPSBC issued Version 1.3 of Interim Guidance on Ketamine Administration via Intramuscular, Oral, Sublingual, Intranasal Routes on August 11, 2025. The document remains interim guidance pending a full practice standard [CPSBC 2025].
• Quebec: Collège des médecins du Québec; Ordre des psychologues du Québec (OPQ). Both the title psychothérapeute and the act of psychotherapy are restricted in Quebec to those holding an OPQ permit, requiring 765 hours of theoretical training and 300 hours of supervised treatment with at least 10 clients [OPQ Regulation, current January 1, 2026].
• Manitoba: College of Physicians and Surgeons of Manitoba (CPSM). CPSM issued Ketamine: What Prescribers and Pharmacists Need to Know on January 20, 2026, stating that "physicians must ensure they have the knowledge, skill, and clinical judgement to prescribe ketamine safely" and detailing requirements for non-hospital IV facilities [CPSM 2026].

For ketamine specifically, training must address provincial regulatory differences. CPSA's Ketamine Prescribing, Administration and Oversight Expectations (March 2026) is the current Alberta authority [CPSA 2026]. ATMA CENA's curriculum builds province-specific content for the Canadian markets where the network operates.

Who can train: eligibility by profession and province

Atomic answer: In most Canadian provinces, the following licensed clinicians are eligible to train in psychedelic-assisted therapy and integrate it into practice within their scope: physicians (MDs, including psychiatrists and family physicians), nurse practitioners, registered psychologists, registered psychotherapists (Ontario), permit-holding psychotherapists (Quebec), registered counsellors, registered nurses, and registered social workers. Specific procedures (prescribing, IV administration, certain assessments) remain restricted to specific scopes. Restricted titles such as psychologist (Alberta, BC, Ontario), Registered Psychotherapist (Ontario), and Psychotherapist (Quebec) apply only to clinicians holding those specific registrations.

Training itself is open broadly. The question is what graduates can do with the training under their provincial scope.

Pathway selection is profession-aware. The Prescriber pathway is designed for independent prescribers (typically MDs and NPs). The Clinical pathway is designed for non-prescribing therapists. The Essentials pathway is open to all registered mental-health professionals and is often the entry point for clinicians evaluating whether to deepen.

Detailed eligibility breakdowns for specific professions are available on dedicated pages: Psychedelic Therapy Training for Physicians, for Counsellors, for Psychotherapists, and for Psychologists.

ATMA CENA's three training pathways

ATMA CENA structures training as three sequential pathways. Each pathway is anchored by the Psychedelic-Assisted Therapy Foundations course as a prerequisite and adds pathway-specific advanced courses, supervised practicum components, and substance-specific modules. The pathways can be taken in sequence or as standalone programs, depending on the clinician's existing competencies and goals.

Essentials pathway (Integrative)

The Essentials pathway introduces foundational concepts of psychedelic-assisted therapy: the history of clinical research, the neurobiology of altered states, the therapeutic frame (set, setting, support), preparation and integration models, ethics, consent, and the Canadian regulatory landscape. It is designed for licensed mental-health clinicians and wellness professionals exploring whether to deepen into clinical PAT delivery, as well as for clinicians who will support patients through preparation and integration without delivering dosing sessions themselves.

→ Read the full Essentials pathway page

Clinical pathway

The Clinical pathway is designed for clinicians who intend to deliver PAT directly with patients. It builds on the Essentials material and adds supervised practicum, role-specific clinical skills, multidisciplinary-team coordination, and assessment competencies including screening, contraindication identification, and integration planning. It is the primary pathway for registered psychotherapists, registered counsellors, registered psychologists, registered nurses, registered social workers, and physicians who plan to act as therapists rather than only as prescribers.

→ Read the full Clinical pathway page

Prescriber pathway

The Prescriber pathway is designed for physicians and other independent prescribers responsible for ketamine prescribing, SAP application authorship, and medical oversight of PAT delivery. It covers ketamine pharmacology and titration, SAP application strategy and writing, cardiovascular and neurological screening, and integration of PAT into a multidisciplinary clinical team. Provincial-college guidance for ketamine prescribing (CPSA, CPSM, CPSO, CPSBC) is built into the curriculum.

→ Read the full Prescriber pathway page

Already trained and ready to bring psychedelic-assisted therapy into your practice? Explore the coordinated care program for clinical protocols, operational systems, and access to a network of trained clinicians.

Substance-specific training: ketamine, psilocybin, MDMA, and integration

Each medicine in the PAT field requires distinct competencies. Comprehensive training covers a shared therapeutic core and then layers on substance-specific knowledge.

Ketamine-assisted psychotherapy (KAT)

Ketamine is the most clinically accessible PAT context in Canada because it is a Health Canada–approved anaesthetic and can be prescribed off-label by licensed physicians under provincial regulatory guidance. Training covers screening, dose-finding, route of administration (intramuscular, intranasal, sublingual, oral, intravenous), session structure, safety monitoring, and integration. Provincial-college guidance varies materially: CPSA Alberta requires CPSA-accredited facilities and psychiatrist oversight [CPSA 2026]; CPSM Manitoba emphasizes prescribing competence and DPIN review [CPSM 2026]; CPSBC BC's interim guidance covers non-IV routes specifically [CPSBC 2025].

The peer-reviewed evidence base for ketamine in treatment-resistant depression continues to expand. Ketamine's rapid antidepressant effect operates through NMDA receptor antagonism that disinhibits glutamate release, activates AMPA receptors, and triggers BDNF-mTOR signalling cascades that promote synaptogenesis, a mechanism synthesized across 141 peer-reviewed publications [Kang, Hawken & Vazquez 2022]. A Canadian community ketamine program in Edmonton, Alberta, reported a 44 percent response rate and 16 percent remission rate among the first 50 ultra-treatment-resistant patients, 90 percent of whom had previously failed electroconvulsive therapy [Chrenek, Duong, Swainson et al. 2023]. A Cochrane systematic review of 64 randomized controlled trials documented esketamine's increased response and remission rates in TRD beginning at 24 hours post-first-dose, with efficacy advantages persisting through 4 weeks compared to placebo [Dean et al. 2021].

Ketamine training competencies are also covered in dedicated advanced courses including Applied Clinical Practice in Psychedelic Therapy, Prescribing & Oversight in Psychedelic-Assisted Therapy, and the optional in-person Ketamine-Assisted Therapy Immersive Experience.

Important notice on ketamine off-label use: Ketamine is a federally approved anaesthetic. In the form of intranasal esketamine (Spravato®), it is also approved by Health Canada for treatment-resistant depression. Use of generic ketamine for depression, anxiety, PTSD, and other mental-health indications is off-label. Off-label prescribing is legally permitted across Canadian provinces; however, provincial college requirements vary. In Alberta, CPSA accreditation is required for facilities offering ketamine-assisted therapy. In British Columbia, CPSBC interim guidance (Version 1.3, August 2025) governs non-IV administration. In Manitoba, CPSM guidance (January 2026) applies. In Ontario, CPSO has no ketamine-specific policy; physicians must demonstrate adequate knowledge, skill, and judgment to prescribe.

Psilocybin-assisted therapy

Psilocybin training is built around the Health Canada SAP framework. Clinicians who train in psilocybin-assisted therapy in Canada are typically working in clinical-trial contexts, in palliative-care settings where end-of-life-distress applications are more frequently approved, or in a supportive role for patients pursuing physician-led SAP applications.

The pivotal peer-reviewed evidence comes from two Phase 2 randomized controlled trials. Goodwin et al. (2022), published in the New England Journal of Medicine, found that a single 25 mg dose of psilocybin produced a 12.0-point reduction in MADRS depression scores at three weeks compared with a 1 mg control dose, a statistically significant between-group difference of 6.6 points (p<0.001) in 233 adults with treatment-resistant depression [Goodwin et al. 2022]. Raison et al. (2023), published in JAMA, replicated efficacy in major depressive disorder: a single 25 mg dose produced a 19.1-point MADRS reduction by day 43 versus 6.8 points for niacin placebo, a between-group difference of 12.3 points (p<0.001), with 42 percent of the psilocybin group achieving sustained response compared with 11 percent on placebo [Raison et al. 2023]. Mechanistic neuroimaging work documents that psilocybin's antidepressant effect correlates with post-treatment decreases in cerebral blood flow in the amygdala and reduced default-mode-network activity [Carhart-Harris et al. 2017].

MDMA-assisted therapy

MDMA training is built around the SAP framework for PTSD specifically. The peer-reviewed evidence base is exceptionally strong. The Phase 3 MAPP1 trial published in Nature Medicine in 2021 found that 67 percent of MDMA-group participants no longer met DSM-5 diagnostic criteria for PTSD at the primary endpoint of 18 weeks, compared to 32 percent in the placebo-with-therapy group, with an effect size of Cohen's d = 0.91 [Mitchell et al. 2021]. The MAPP2 confirmatory Phase 3 trial published in Nature Medicine in 2023 reproduced the result in moderate-to-severe PTSD: 71.2 percent of MDMA-AT participants no longer met PTSD criteria versus 47.6 percent of the placebo group (p<0.001; d=0.70) [Mitchell et al. 2023]. Both trials used a manualized therapy protocol involving preparation, MDMA sessions, and integration; therapist dyads using the manualized protocol demonstrated high cross-site fidelity in independent adherence assessment [Wang et al. 2021].

Important regulatory notice: Psilocybin and MDMA are Schedule III controlled substances in Canada. They are not commercially approved drugs. Access for clinical use is available only through Health Canada's Special Access Program, on a patient-by-patient basis, subject to individual Health Canada authorization. SAP requests are assessed case by case; authorization is not guaranteed. As of September 2025, approval rates have declined significantly. Completion of any training program does not constitute authorization to administer psilocybin or MDMA. SAP applications must be submitted by an authorized prescriber.

Integration psychotherapy

Integration is the post-dosing therapeutic work that translates a psychedelic experience into lasting change in the patient's life. A systematic review of 52 psychedelic clinical trials found that integration sessions were present in all but 9, and that the quality of the psychedelic experience and the therapeutic alliance during preparation predicted clinical improvement [Breeksema et al. 2022]. Integration is defined in the peer-reviewed literature as "any conscious and informed attempt to facilitate processing the psychedelic experience content or resulting consequences, in order to implement its relevant outcomes into everyday life" [Gorman et al. 2021]. The Psychedelic Harm Reduction and Integration framework (Gorman, Nielson, Molinar et al., 2021) and the EMBARK transdiagnostic framework (Brennan & Belser, 2022) provide structured clinical models that ATMA CENA's curriculum draws on.

Integration competencies are necessary regardless of which medicine the patient received. Clinicians who do not deliver dosing sessions can serve as integration therapists for patients who received PAT in clinical trials or under SAP authorization. Dedicated integration training is covered in Psychedelic Integration Training.

The course structure: from foundations to supervised practicum

ATMA CENA's training combines didactic learning, advanced pathway-specific courses, supervised clinical labs, and optional in-person experiential practicum. The structure is competency-based, building from foundational concepts to direct clinical practice.

Foundations (prerequisite for all pathways): The 14-hour Psychedelic-Assisted Therapy Foundations course covers history, neurobiology, ethics, the therapeutic frame, screening, and the Canadian regulatory landscape. It is the entry point for every pathway.

Pathway-specific advanced courses:

• Applied Clinical Practice in Psychedelic Therapy (55 hours) builds on Foundations and prepares clinicians in the Clinical pathway for direct PAT delivery, including substance-specific protocols and case-formulation skills.
• Advanced Safety & Support Practices in Psychedelic-Assisted Therapy (39 hours) anchors the Integrative pathway and covers preparation, integration, and supportive-role competencies.
• Prescribing & Oversight in Psychedelic-Assisted Therapy (40 hours) anchors the Prescriber pathway and covers ketamine prescribing, SAP application authorship, and team oversight.

Supervised practicum: The Supervised Learning Lab (8 hours) is a small-group live clinical-skills lab where trainees rehearse session structure with experienced facilitators. Health Canada's clinical-trial expectations note that "any unlicensed members of the therapy team should be under the direct supervision of a licensed therapist" and that two therapists are required during medicine administration [Health Canada 2022], underscoring why supervised practicum is foundational.

Optional experiential practicum: The Ketamine-Assisted Therapy Immersive Experience is a three-day in-person practicum where trainees observe and co-facilitate dosing sessions under supervision.

The number of supervised hours required to reach competence is an active area of discussion in the PAT literature. No published study has yet quantified the dose-response relationship between supervision hours and therapist competence outcomes. Phelps (2017) and Tai et al. (2021) describe components of effective training but do not specify a single required hour count. ATMA CENA's pathway hours reflect the network's clinical experience and align with the components emphasized in the published literature.

Certifications, CE credits, and professional recognition

Continuing-education recognition matters because most Canadian regulators require ongoing competency development to maintain licensure. The CE landscape varies by regulator:

• Physicians (MDs): The Royal College of Physicians and Surgeons of Canada accredits CPD activities through the Maintenance of Certification program (MOC Section 1, 2, 3). The College of Family Physicians of Canada accredits through Mainpro+. Both bodies updated their credit frameworks in 2024–2025 with new self-claim options for eLearning.
• Counsellors (CCCs): The Canadian Counselling and Psychotherapy Association requires 36 continuing-education hours per three-year cycle. As of January 1, 2025, CCPA moved to a Continuing Education Trust System under which members self-attest, with audit-based verification. Members are still required to complete 36 hours regardless of the new submission process.
• Psychologists: The Canadian Psychological Association approves CE programs nationally. The College of Alberta Psychologists recognizes CE in line with the June 2025 PAP guideline. The Ordre des psychologues du Québec mandates 90 hours of continuing education in psychotherapy over a 5-year period for psychotherapist permit-holders [OPQ Regulation].
• Registered Psychotherapists (Ontario): CRPO requires participation in the Continuing Competency Program and ongoing professional-development activity, with reporting requirements specified in the College's standards.

Online versus in-person training: what the evidence shows

Atomic answer: Online didactic delivery suits foundational and theoretical content. Supervised practicum, experiential learning, and dosing-day skills require in-person or hybrid delivery. Peer-reviewed evidence supports a blended model: Tai et al. (2021) evaluated a four-component psilocybin therapist training combining online learning, a five-day in-person workshop, supervised research sessions, and ongoing mentoring, with high satisfaction across 65 trainees [Tai et al. 2021]. Dames et al. (2024) argue in Psychedelic Medicine that "firsthand subjective experience of PaT is a crucial training element for PaT practitioners," a competency that cannot be fully developed through didactic delivery alone [Dames et al. 2024].

ATMA CENA's pathways follow the blended model. Didactic modules in Foundations and the pathway-specific advanced courses are available online, providing flexibility for clinicians balancing training with active practice. Supervised practicum (Supervised Learning Lab) and experiential components (KAT Immersive Experience) are delivered in-person to ensure direct supervision and rehearsal of dosing-day skills. The peer-reviewed case for personal experiential exposure remains an active professional discussion rather than a settled clinical standard. Health Canada SAP protocols do not mandate personal psychedelic experience as a training prerequisite. Different programs make different choices on this question.

How to become a certified psychedelic therapist in Canada

Becoming a certified PAT clinician in Canada follows five stages. The path varies in detail by profession but holds the same general shape.

Stage 1 — Confirm your provincial registration. PAT training does not confer licensure. It builds competencies on top of an existing licence. Confirm that you are in good standing with your provincial regulator (CRPO, CAP, OPQ, CCPA-recognized college, provincial College of Nurses or Social Workers, College of Physicians and Surgeons in your province).

Stage 2 — Complete foundational training. The 14-hour Foundations course is the prerequisite for all ATMA CENA pathways. It establishes shared vocabulary and the regulatory landscape relevant to PAT in Canada.

Stage 3 — Choose and complete a pathway-specific track. Clinical, Prescriber, or Integrative, depending on your scope and goals. Each pathway adds advanced courses (39–55 hours of didactic content) and substance-specific modules.

Stage 4 — Complete supervised practicum. The Supervised Learning Lab and (optionally) the KAT Immersive Experience provide the supervised practice that prepares clinicians for direct PAT delivery. Health Canada clinical-trial expectations require licensed-therapist supervision of any unlicensed team members and two therapists during medicine administration [Health Canada 2022].

Stage 5 — Maintain ongoing CE and supervision. PAT is an evolving field. Regulator CE requirements (36 hours per three years for CCCs; 90 hours per five years for OPQ permit-holders; MOC credits for physicians) ensure ongoing competence. ATMA CENA's network supports graduates with continuing supervision, case consultation, and access to advanced CE.

For a more detailed walkthrough of the certification process, see How to Get Psychedelic Therapy Certification in Canada.

Find psychedelic therapy training near you

ATMA CENA's didactic training is available online to clinicians anywhere in Canada. In-person practicum components (Supervised Learning Lab, KAT Immersive Experience) are offered at the corporate training centres in Edmonton, Alberta and Calgary, Alberta. ATMA CENA's clinical network additionally includes member clinics in Hamilton, Kitchener-Waterloo, London, Mississauga, Oakville, Sarnia, North Bay, Vaughan, and Windsor (Ontario); Montreal (Quebec); Saskatoon (Saskatchewan); and Winnipeg (Manitoba). Graduates of the Clinical and Prescriber pathways can join the coordinated care program to integrate PAT delivery into their existing practice within the network.

Province-specific training pages provide further detail on regulatory considerations and CE-credit applicability for each Canadian province: Alberta, Ontario, British Columbia, Quebec, and online delivery options.

Frequently asked questions

Is psychedelic-assisted therapy training legal in Canada?

Yes. Training to deliver supervised therapy with psychedelic medicines is legal in Canada. The medicines themselves are regulated separately. Ketamine is a Health Canada–approved anaesthetic that can be prescribed off-label for mental-health indications under provincial-college guidance. Psilocybin and MDMA remain Schedule III restricted drugs; patient access requires a physician-led Special Access Program application to Health Canada, which is granted on a case-by-case basis.

Do I need to be a physician to train in psychedelic-assisted therapy?

No. Training is open to a range of registered mental-health professionals including registered psychotherapists (Ontario), permit-holding psychotherapists (Quebec), registered counsellors, registered psychologists, registered nurses, and registered social workers, in addition to physicians and nurse practitioners. The Prescriber pathway is specifically designed for independent prescribers. The Clinical pathway is designed for non-prescribing therapists. The Essentials pathway is the entry point for all professions.

How long does psychedelic therapy training take?

Time-to-completion varies by pathway and by the clinician's prior experience. The Foundations course is 14 hours of didactic content. Pathway-specific advanced courses range from 39 to 55 hours. Supervised practicum components add additional time. Many clinicians complete a full pathway over 6 to 18 months while continuing active practice.

What CE or CME credits do ATMA CENA's pathways carry?

How much does psychedelic therapy training cost in Canada?

Can I train online?

Yes, for the didactic components. The Foundations course and the didactic portions of the pathway-specific advanced courses are delivered online. Supervised practicum components (Supervised Learning Lab, KAT Immersive Experience) are in-person to ensure direct supervision of clinical skills.

What is the difference between psychedelic-assisted therapy training and psychedelic integration training?

PAT training (Clinical or Prescriber pathway) prepares clinicians to deliver the full therapeutic frame including preparation, supervised dosing, and integration. Integration training prepares clinicians to deliver only the integration component, which is the post-experience therapeutic work that helps patients translate a psychedelic experience into lasting change. Integration-only clinicians are valuable in serving patients who received PAT elsewhere, including in clinical trials or under SAP authorization. See Psychedelic Integration Training for more detail.

Is ketamine-assisted therapy training the same as psychedelic-assisted therapy training?

There is significant overlap, but the curricula are not identical. Ketamine has different pharmacology, screening considerations, and provincial regulatory framing from psilocybin and MDMA. Comprehensive PAT training covers the shared therapeutic core and adds substance-specific layers. The KAT-focused content is integrated into the Clinical and Prescriber pathways and is detailed further on the Ketamine-Assisted Psychotherapy Training in Canada page.

Is personal psychedelic experience required to train as a PAT clinician?

Health Canada SAP protocols do not mandate personal psychedelic experience as a training prerequisite. Some training programs offer or require experiential components; others do not. The peer-reviewed case for firsthand experience as a competency-critical element [Dames et al. 2024] is an argumentative and survey-based position rather than a settled clinical standard. ATMA CENA's KAT Immersive Experience is an optional in-person practicum offered to clinicians who choose it.

Can I train in Canada and practise in another province?

Generally yes, with the caveat that your professional registration must be valid in the province where you practise, and your scope of practice is governed by that province's regulator. Training does not transfer registration. Clinicians intending to practise in a province other than their training jurisdiction should review the relevant provincial-college guidance.

What happens after I complete training?

Graduates of the Clinical and Prescriber pathways can join ATMA CENA's coordinated care program to integrate PAT delivery into their existing or new practice with clinical protocols, operational systems, and access to a network of trained clinicians. See coordinated care overview and clinician resources for further detail.

Has the Vancouver Island University psychedelic-assisted therapy graduate certificate been discontinued?

Yes. Vancouver Island University discontinued its Graduate Certificate in Psychedelic-Assisted Therapy in November 2025. Clinicians who were exploring that program may find ATMA CENA's pathways a Canadian-context alternative. ATMA CENA is not affiliated with VIU.

Apply, book an info call, or explore the course catalogue

Ready to begin? Start with the Psychedelic-Assisted Therapy Foundations course, which is the prerequisite for all three pathways, or talk to a clinical advisor to choose the right path for your credentials, province, and goals. Already trained and ready to bring PAT into your existing practice? Explore the coordinated care program.

For physicians considering the Prescriber pathway, the Prescriber Pathway page details cardiovascular and neurological screening, ketamine titration, and SAP application authorship. For non-prescribing therapists, the Clinical Pathway page covers direct delivery competencies. For wellness professionals and integration-focused clinicians, the Integrative (Essentials) Pathway page covers preparation, integration, and supportive-role skills.

Sources

1. Health Canada (2022). Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
2. Health Canada (2022). Notice to stakeholders: Health Canada's expectations regarding risk-management measures for clinical trials involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/expectations-risk-management-measures-clinical-trials-psychedelic-assisted-psychotherapy.html
3. Psychedelic Association of Canada (2025). PsyCan Discovers Sharp Decline in Health Canada Approvals for Doctors Seeking Legal Psychedelic Therapy for Patients. https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
4. Mitchell, J.M. et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033. https://www.nature.com/articles/s41591-021-01336-3
5. Mitchell, J.M. et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10), 2473–2480. https://www.nature.com/articles/s41591-023-02565-4
6. Goodwin, G.M. et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387, 1637–1648. https://www.nejm.org/doi/full/10.1056/NEJMoa2206443
7. Raison, C.L. et al. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://jamanetwork.com/journals/jama/article-abstract/2808950
8. Carhart-Harris, R.L. et al. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 7, 13187. https://www.nature.com/articles/s41598-017-13282-7
9. Kang, M.J.Y., Hawken, E. & Vazquez, G.H. (2022). The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity. Frontiers in Psychiatry, 13:860882. https://pmc.ncbi.nlm.nih.gov/articles/PMC9082546/
10. Chrenek, C., Duong, B., Khullar, A., McRee, C., Thomas, R. & Swainson, J. (2023). Use of ketamine for treatment-resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada. Frontiers in Psychiatry, 14:1283733. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1283733/full
11. Dean, R.L. et al. (2021). Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. Cochrane Database of Systematic Reviews. https://pmc.ncbi.nlm.nih.gov/articles/PMC10399093/
12. Tai, S.J. et al. (2021). Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression. Frontiers in Psychiatry, 12:586682. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.586682/full
13. Wang, J.B. et al. (2021). Therapeutic alliance among MDMA-assisted therapy in PTSD trials: a multisite study. Journal of Humanistic Psychology. https://journals.sagepub.com/doi/10.1177/00221678211023663
14. Phelps, J. (2017). Developing Guidelines and Competencies for the Training of Psychedelic Therapists. Journal of Humanistic Psychology, 57(5), 450–487. https://journals.sagepub.com/doi/abs/10.1177/0022167817711304
15. Hartogsohn, I. (2018). The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Assisted Therapies. Frontiers in Neuroscience, 12:129. https://pmc.ncbi.nlm.nih.gov/articles/PMC5845636/
16. Breeksema, J.J. et al. (2022). Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies. CNS Drugs. https://pmc.ncbi.nlm.nih.gov/articles/PMC9226617/
17. Gorman, I., Nielson, E.M., Molinar, A., Cassidy, K. & Sabbagh, J. (2021). Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Frontiers in Psychology, 12:645246. https://pmc.ncbi.nlm.nih.gov/articles/PMC8008322/
18. Brennan, W. & Belser, A.B. (2022). Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. Frontiers in Psychology, 13:866018. https://pmc.ncbi.nlm.nih.gov/articles/PMC9201428/
19. Dames, S., Watler, K., Kryskow, P. et al. (2024). Why Firsthand Subjective Experience of Nonordinary States of Consciousness is a Crucial Training Element for Psychedelic-Assisted Therapy Practitioners. Psychedelic Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC11658659/
20. College of Physicians and Surgeons of Alberta (2026). Ketamine Prescribing, Administration and Oversight Expectations (March 2026). https://cpsa.ca/wp-content/uploads/2026/03/CPSA_Ketamine-Guidance_March-2026.pdf
21. College of Physicians and Surgeons of Manitoba (2026). Ketamine: What Prescribers and Pharmacists Need to Know (January 2026). https://www.cpsm.mb.ca/news/ketamine-what-prescribers-and-pharmacists-need-to-know
22. College of Physicians and Surgeons of British Columbia (2025). Interim Guidance: Ketamine Administration via Intramuscular, Oral, Sublingual, Intranasal Routes (Version 1.3, August 2025). https://www.cpsbc.ca/files/pdf/IG-Ketamine-Administration-via-Intramuscular-Oral-Sublingual-Intranasal-Routes.pdf
23. College of Alberta Psychologists (2025). Practice Guideline: Psychedelic-Assisted Psychotherapy (June 2025). https://www.cap.ab.ca/Portals/0/adam/Content/fQCpza4q7EGXC_psrgnCvA/Link/Psychedelic-Assisted%20Psychotherapy%20-%20June%202025.pdf
24. College of Registered Psychotherapists of Ontario. Practice Standard 6.2: Advertising. https://crpo.ca/practice-standards/business-practices/advertising/
25. Ordre des psychologues du Québec / Légis Québec. Regulation respecting the psychotherapist's permit (C-26, r. 222.1) (current January 1, 2026). https://www.legisquebec.gouv.qc.ca/en/document/cr/C-26,%20r.%20222.1%20/

Related articles in this cluster

• Ketamine-Assisted Psychotherapy Training in Canada
• Psilocybin Therapy Training in Canada
• MDMA-Assisted Therapy Training in Canada
• Psychedelic Integration Training
• Psychedelic Therapy Training for Physicians
• Psychedelic Therapy Training for Counsellors
• Psychedelic Therapy Training for Psychotherapists
• Psychedelic Therapy Training for Psychologists
• Psychedelic Therapy Training Cost in Canada
• Which Psychedelic Therapy Training Pathway Is Right for Me?
• How to Become a Psychedelic Therapist in Canada
• How to Get Psychedelic Therapy Certification in Canada
• CE Credits for Psychedelic Therapy Training in Canada
• Psychedelic Therapy Training in Alberta
• Psychedelic Therapy Training in Ontario
• Practitioner FAQs
• ATMA CENA Licensing & Accreditation
• Find care near you

Last updated: 2026-05-05. Article is reviewed every 6 months.